No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection

2017 ◽  
Vol 24 (10) ◽  
pp. 808-813 ◽  
Author(s):  
O. El Sherif ◽  
N. Afhdal ◽  
M. Curry
Keyword(s):  
Hepatitis C ◽  
Genotype 1 ◽  
Direct Acting Antivirals ◽  
Duration Of Therapy ◽  
Direct Acting

scholarly journals Sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals

2018 ◽  
Vol 12 (4) ◽  
pp. 356-367 ◽  
Author(s):  
Namiki Izumi ◽  
Tetsuo Takehara ◽  
Kazuaki Chayama ◽  
Hiroshi Yatsuhashi ◽  
Koichi Takaguchi ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Japanese Patients ◽  
Genotype 1 ◽  
Direct Acting Antivirals ◽  
Direct Acting

Treatment Outcomes for Hepatitis C Genotype 1 Infection with Direct Acting Antivirals: Data from the German Hepatitis C-Registry

2016 ◽  
Vol 64 (2) ◽  
pp. S820 ◽  
Author(s):  
S. Mauss ◽  
P. Buggisch ◽  
K.H.W. Böker ◽  
E. Schott ◽  
H. Klinker ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Treatment Outcomes ◽  
Genotype 1 ◽  
Direct Acting Antivirals ◽  
Direct Acting

scholarly journals Hepatitis C Resistance-Associated Substitutions Among People Who Inject Drugs Treated with Direct-Acting Antiviral-Containing Regimens

2021 ◽  
Author(s):  
Matthew J Akiyama ◽  
Lindsey Riback ◽  
Jacqueline D Reeves ◽  
Yolanda S Lie ◽  
Linda Agyemang ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Protease Inhibitor ◽  
People Who Inject Drugs ◽  
Virologic Failure ◽  
Late Relapse ◽  
Resistant Virus ◽  
Genotype 1 ◽  
Direct Acting Antivirals ◽  
Direct Acting Antiviral ◽  
Direct Acting

Abstract Background Resistance-associated substitutions (RASs) to HCV direct-acting antivirals (DAAs) can contribute to virologic failure and limit retreatment options. People who inject drugs (PWID) are at highest risk for transmission of resistant virus. We report on RASs at baseline and following virologic failure in DAA-naive and protease inhibitor-experienced PWID. Methods We sequenced the NS3/4A, NS5A, and NS5B regions from 150 PWID with genotype 1 (GT1) viruses; 128 (85.3%) GT1a, 22 (14.7%) GT1b. Results Among the 139 (92.7%) DAA-naive PWID, 85/139 (61.2%) had baseline RASs – 67/139 (48.2%) in NS3 (predominantly Q80K/L); 25/139 (18.0%) in NS5A; and 8/139 (5.8%) in NS5B. Of the 11 protease inhibitor-experienced participants, 9 had baseline NS3 RASs (V36L N=1, Q80K N=9) and 4 had baseline NS5A RASs (M28V N=2, H58P N=1, A92T N=1). Among the 11 participants who had post-treatment samples with detectable virus (seven treatment failures, one late relapse, three reinfections), one sofosbuvir/ledipasvir failure had a baseline H58P. Two sofosbuvir/ledipasvir-treated participants developed new NS5A mutations (Q30H, Y93H, L31M/V). Otherwise, no RASs were detected. Conclusion Our results demonstrate RAS prevalence among DAA-naive PWID is comparable to that in the general population. Only 2/150 (1.3%) in our longitudinal cohort developed treatment-emergent RASs. Concern for transmission of resistant virus may therefore be minimal.

Impact of IFNL4 -∆G genotype on sustained virologic response in hepatitis C genotype 1 patients treated with direct-acting antivirals

2018 ◽  
Vol 92 (1) ◽  
pp. 34-36 ◽  
Author(s):  
Lisa I. Backus ◽  
Troy A. Shahoumian ◽  
Pamela S. Belperio ◽  
Mark Winters ◽  
Ludmila Prokunina-Olsson ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Sustained Virologic Response ◽  
Virologic Response ◽  
Genotype 1 ◽  
Direct Acting Antivirals ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document